Finance

Lists
Why is ARDT up 3,33%?
Dive Deeper
ARDT:NYSE
Ardent Health Inc
USD 12,09
+3,33%
(+0,39) 1D
20 Okt., 14:16:14 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARDT...
Open
USD 11,84
High
USD 12,12
Low
USD 11,84
Mkt. cap
1,71 mjd
Avg. vol.
489,75 k
Volume
163,53 k
P/E ratio
22,01
52-wk high
USD 15,48
52-wk low
USD 7,71
EPS
USD 0,55
Shares outstanding
141,05 m
No. of employees
22 k
Open
USD 11,84
High
USD 12,12
Low
USD 11,84
Mkt. cap
1,71 mjd
Avg. vol.
489,75 k
Volume
163,53 k
P/E ratio
22,01
52-wk high
USD 15,48
52-wk low
USD 7,71
EPS
USD 0,55
Shares outstanding
141,05 m
No. of employees
22 k
News stories
From web sources and news partners
About Ardent Health Inc
CEO-
Employees22,4 k
Founded2001
Headquarters-
SectorHealth care provider
Websiteardenthealth.com
Analyst ratings
Based on 9 analysts giving stock ratings to ARDT in the past 3 months
Buy
Buy
5
Hold
3
Sell
1
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ARDT in the last 3 months.
Highest
Current USD 12,09
USD 14,00 (+15,80%)
Average
USD 12,29 (+1,65%)
Lowest
USD 10,00 (-17,29%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ben Hendrix
RBC Capital
Buy
Maintained
USD 13,00
+7,5%
10/07/2026
David S Macdonald
Truist Financial
Buy
Maintained
-
-
09/30/2026
Sean Dodge
BMO Capital
Hold
Initiated
USD 11,00
-9%
09/23/2026
Whit Mayo
Leerink Partners
Buy
Reiterated
-
-
09/17/2026
Scott Fidel
Goldman Sachs
Hold
Maintained
USD 13,00
+7,5%
08/10/2026
Kevin Fischbeck
Bank of America Securities
Sell
Reiterated
USD 10,00
-17,3%
08/10/2026
Craig Hettenbach
Morgan Stanley
Hold
Reiterated
USD 12,00
-0,7%
08/06/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
USD 13,00
+7,5%
08/06/2026
Jason Cassorla
Guggenheim
Buy
Maintained
USD 14,00
+15,8%
08/05/2026
Jailendra Singh
Truist Financial
Buy
Reiterated
-
-
06/03/2026
A.J. Rice
UBS
Buy
Reiterated
USD 13,50
+11,7%
06/03/2026
Matthew Gillmor CFA
KeyBanc
Hold
Maintained
-
-
06/03/2026
Irene Nattel
RBC Capital
Buy
Maintained
USD 13,00
+7,5%
05/07/2026
Unknown Analyst
Stephens
Buy
Maintained
USD 14,00
+15,8%
03/06/2026
Last report
05 Aug. 2026
Fiscal period
Q2 2026
USD 0,27 / USD 0,19
+43,95%beat
Revenue / Est. (USD)
1,62 mjd / 1,59 mjd
+2,05%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,58 mjd
1,61 mjd
1,60 mjd
1,62 mjd
Cost of goods sold
676,96 m
651,39 m
661,43 m
676,19 m
Cost of revenue
676,96 m
651,39 m
661,43 m
676,19 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
645,46 m
653,77 m
651,39 m
674,11 m
Operating expense
883,33 m
848,94 m
859,53 m
890,29 m
Total operating expenses
1,56 mjd
1,50 mjd
1,52 mjd
1,57 mjd
Operating income
16,46 m
104,75 m
80,91 m
55,77 m
Other non operating income
-
1,80 m
5,89 m
-
EBT including unusual items
-2,20 m
92,37 m
74,59 m
43,20 m
EBT excluding unusual items
2,54 m
94,17 m
74,59 m
43,20 m
Income tax expense
-3,41 m
18,11 m
16,10 m
8,51 m
Effective tax rate
154,79%
19,60%
21,59%
19,71%
Other operating expenses
198,71 m
154,13 m
165,15 m
174,84 m
Net income
-23,48 m
44,96 m
39,85 m
16,90 m
Net profit margin
-1,49%
2,80%
2,49%
1,04%
Earnings per share
0,83
0,36
0,30
0,27
Interest and investment income
-
-
-
-
Interest expense
-13,91 m
-12,38 m
-12,21 m
-12,57 m
Net interest expenses
-13,91 m
-12,38 m
-12,21 m
-12,57 m
Depreciation and amortization charges
39,16 m
41,04 m
42,99 m
41,34 m
EBITDA
55,61 m
145,79 m
123,90 m
97,11 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme